About Janux Therapeutics
Janux Therapeutics is a publicly listed company based in San Diego (United States) founded in 2017 by David Campbell. Immunotherapeutics for cancer treatment are developed to target solid tumors. Janux Therapeutics has raised $181 million across 2 funding rounds from investors including Citadel, Orbimed and Janus Henderson Investors. The company has 81 employees. Its chief executive, as recorded, is David Campbell. Janux Therapeutics offers products and services including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008). Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is JANUX THERAPEUTICS, INC. Its competitors include Sana Biotechnology, GigaGen and Kronos Bio; 3 of its 3 listed competitors have raised funding.
Company details
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, United States. Focus is placed on the biotechnology sector, specifically oncology, where immunotherapeutics are developed for solid tumors such as colorectal, gastroesophageal, prostate, NSCLC, triple-negative breast, and ovarian cancers. Lead candidates include TROP2-TRACTr, PSMA-TRACTr, EGFR-TRACTr, HER2-TRACTr, and costim bispecifics. T cell engagers that bind tumor cells and activate patient T-cells for tumor eradication are also being advanced.
- Headquarters San Diego, United States
- Employees 81
- Founders David Campbell
- Stage Public
- SectorsHealthcare
- Website januxrx.com
- Social LinkedIn X
- Legal Name Janux Therapeutics, Inc.
- Annual Revenue$10 M (USD)-5.55as on Dec 31, 2025
- Net Profit-$113.63 M (USD)-64.69as on Dec 31, 2025
- EBITDA-$155.64 M (USD)-60.8as on Dec 31, 2025
- Total Equity Funding$181M (USD)
in 2 rounds
- Latest Funding Round$125M (USD), Series B
Apr 2021
- InvestorsCitadel
& 10 more
- Employee Count81
Products & Services of Janux Therapeutics
Janux Therapeutics offers a comprehensive portfolio of products and services, including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Tumor-activated T cell engager targeting prostate cancer
Tumor-activated T cell engager for EGFR-related cancers
Funding Insights of Janux Therapeutics
Janux Therapeutics has successfully raised a total of $181M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $181M
- Total Rounds 2
- Last Round Series B — $125M
- First Round $56M
(Mar 2021)
- Investors Count 11
All 2 funding rounds of Janux Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $125M | Series B | – | RA Capital Management | |
| Mar 2021 | $56M | Series A | – | Avalon Ventures |
11 investors in total: 11 institutional.
Investors in Janux Therapeutics
Janux Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital firm focused on aerospace, biopharma, consumer, and multiple sectors | correlationvc.com | San Francisco, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| ecor1cap.com | ||||
Multi-specialty hospital services are operated through a chain. | 1854 | hartfordhospital.org | United States |
Investor details for Janux Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Janux Therapeutics
77 people are tracked at Janux Therapeutics (31 in leadership, 12 in board & advisors, 34 in team); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
David Campbell | Founder & CEO & President | Leadership |
Ying Zhang | Associate Director | Leadership |
Zachariah McIver | Chief Medical Officer | Leadership |
Roger Lis | Associate Director Clinical Operations | Leadership |
Andy Meyer | Chief Business Officer | Leadership |
Byron Robinson | Chief Strategy Officer | Leadership |
Melody Bradley | Director Of Quality Assurance | Leadership |
Janeen Doyle | Chief Corporate And Business Development Officer | Leadership |
Anne Rollins | Director, Clinical Operations, EGFR Asset Lead | Leadership |
Megan Shannon | Executive Director, Clinical Science | Leadership |
Tighe Reardon | Acting CFO | Leadership |
Jenna Daly | Executive Director Clinical Operations | Leadership |
Charles Winter | CTO | Leadership |
Sean Casey | Director Of Data Management | Leadership |
Maria Dobek, CPA | Vice President, Accounting | Leadership |
Natalija Van Braeckel Budimir | Director, Immunology | Leadership |
Yogesh Bramhecha, PhD | Director, Biomarker Discovery | Leadership |
Sara Walsh | Executive Administrative Assistant to the President and Chief Executive Officer | Leadership |
Carolina Caffaro | Vice President, CMC | Leadership |
Tommy DiRaimondo | Executive Director, Research & Development | Leadership |
57 more people are available in the full profile.
Complete people profiles for Janux Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Janux Therapeutics
Janux Therapeutics is a publicly listed company on the NASDAQ with ticker symbol JANX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Jun 2021
- Listed onNASDAQ: JANX
- Listed entityJanux Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS47103J1051
- Share price$17.18 (-5.34% on the day) · 2026-10-13
- Market capitalisation$1.05B
- EPS (diluted, trailing year)$-1.64
- Volume (last session)794,897
Financials of Janux Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $10.0M | -$113.6M | -$155.6M |
| 2024 | $10.6M | -$69.0M | -$96.8M |
| 2023 | $8.1M | -$58.3M | -$71.0M |
| 2022 | $8.6M | -$63.1M | -$66.2M |
| 2021 | $3.6M | -$32.7M | -$32.8M |
Detailed financial statements for Janux Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Janux Therapeutics
4 dated milestones of Janux Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Janux Therapeutics is founded.
- Funding First funding round of $56.0M.
- Funding Latest funding round, Series B, of $125.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Janux Therapeutics
Janux Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Sana Biotechnology, GigaGen and Kronos Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| kronosbio.com | 2017 | San Mateo, United States | $271.01M | 97 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Janux Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Janux Therapeutics
The website of Janux Therapeutics (januxrx.com) receives about 10K visits a month.
- Monthly visits10K
▼ 38.8% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Janux Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Janux Therapeutics
Complete news archive for Janux Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Janux Therapeutics
Janux Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Janux Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
David Campbell is the CEO of Janux Therapeutics, as recorded in our data. They have also founded this company.
Janux Therapeutics is a funded company, having raised a total of $181M across 2 funding rounds to date. The company's 1st funding round was a Series A of $56M, raised on Mar 2021.
Janux Therapeutics has 81 employees.
Annual revenue of Janux Therapeutics is $10M as on Dec 31, 2025.
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, United States. Focus is placed on the biotechnology sector, specifically oncology, where immunotherapeutics are developed for solid tumors such as colorectal, gastroesophageal, prostate, NSCLC, triple-negative breast, and ovarian cancers. Lead candidates include TROP2-TRACTr, PSMA-TRACTr, EGFR-TRACTr, HER2-TRACTr, and costim bispecifics. T cell engagers that bind tumor cells and activate patient T-cells for tumor eradication are also being advanced.
Janux Therapeutics's top competitors include Kronos Bio, Sana Biotechnology and GigaGen.
Janux Therapeutics offers PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Yes, Janux Therapeutics is publicly traded on NASDAQ under the ticker symbol JANX.
Janux Therapeutics has 11 investors. Key investors include Citadel, Orbimed, Janus Henderson Investors, RA Capital, and Hartford Hospital.
Janux Therapeutics operates through Janux Therapeutics, Inc..